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Mucin glycoproteins play an important role in protecting the gut epithelium by keeping gut microbes from direct contact with the gut epithelium
while allowing for diffusion of small molecules from the lumen to the
epithelium. The mucin glycocalyx can be degraded by gut bacteria such as
Bacteroides and Akkermansia, but other bacteria, such as Bifidobacterium longum subsp. Infantis, cannot consume mucin glycans. Untargeted
mass spectrometry profiles were compared to microbiome profiles to assess
how different gut microbiomes affect colonic mucin degradation. Samples
obtained from nine infants colonized by Bifidobacterium infantis EVC001
and from 10 infants colonized by higher levels of mucolytic taxa (controls),
including Bacteroides, were compared. Previously performed untargeted
nano-high-performance liquid chromatography-chip/time-of-flight mass
spectrometry was used to detect and quantify glycans originating from
colonic mucin. Colonic mucin-derived O-glycans from control infants composed 37.68% ( 3.14% SD) of the total glycan structure pool, whereas
colonic mucin-derived O-glycans made up of only 1.78% ( 0.038% SD)
of the total in B. infantis EVC001 samples. The relative abundance of these
colonic mucin-derived O-glycans in the total glycan pool was higher among
control, 26.98% ( 8.48% SD), relative to B. infantis-colonized infants,
1.68% ( 1.12% SD). Key taxa, such as Bacteroidaceae, were significantly
and positively correlated with the abundance of these structures, while Bifidobacteriaceae were significantly and negatively associated with these structures. These results suggest that colonization of infants by B. infantis may
diminish colonic glycan degradation and help maintain barrier function in
the gastrointestinal tract of infants.

Mucins are highly glycosylated O-linked glycoproteins
secreted by exocrine glands and mucosa. They contain
a wide variety of glycan structures, which make up
80% of the glycoprotein mass. These glycans attach to
the polypeptide backbone via serine or threonine

residues with N-acetylgalactosamine. Eight O-glycan
cores have been identified [1]. Among these cores, core
1-, 2-, 3-, and 4-derived glycans are predominantly
found in intestinal mucins. Specifically, core 1 (Galb1–
3GalNAca1-Ser/Thr)
and
core
2
(Galb1,3

Abbreviations
ACN, acetonitrile; FA, formic acid; FDR, false discovery rate; GH, glycosyl hydrolase; HMO, human milk oligosaccharide; HPLC, highperformance liquid chromatography; OS, oligosaccharide; OTU, operational taxonomic unit; PCoA, principal coordinate analysis; TOF, time of
flight.
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(GlcNAcb1,6)GalNAca1-Ser/Thr) structures are found
in gastric and duodenal mucins, whereas colonic mucins
contain predominantly core 3, 4 (GlcNAcb1,6
(GlcNAcb1,3) GalNAcaSer/Thr) elongated structures
[2,3]. Mucin degradation by mucolytic taxa like Bacteroides is achieved with a wide variety of enzymes, such
as proteases, sulfatases, fucosidases, neuraminidases, bgalactosidases, a-N-acetylgalactosaminidases, a-N-acetylglucosaminidases, and exo/endo-b-N-acetyl-glucosaminidases [4]. Although the presence of mucin-consuming
taxa is associated with increased mucin production, it is
unclear whether this is a beneficial trait as the breakdown of the mucin barrier is often associated with negative impacts to the underlying gut epithelium [5], and its
loss can be a pathway to infection [6], loss of gut epithelial barrier function [7], or spontaneous inflammation
resembling colitis [8]. Further, mucin degradation provides a niche that fosters taxa whose cytotoxic products
can lead to colon cancer [9].
Human milk contains structurally analogous carbohydrates in the form of N-linked and O-linked
glycoproteins and glycolipids [10] as well as free glycans, known as human milk oligosaccharides
(HMOs) [11]. Several gut bacteria found in breastfed
infants are able to release and consume mucin glycans (e.g., Bacteroides), and while some species of
Bifidobacterium (e.g., B. bifidum) are able to grow on
mucin as a sole carbon source, others can not (e.g.,
Bifidobacterium infantis) [12]. Interestingly, the taxa
that consume both mucin glycans and HMOs appear
to use the same glycolytic capacities and regulatory
networks to consume these structures, whereas specialized taxa consume HMOs in unique pathways,
and appear to only express these genes in response
to a limited number of carbohydrates [13–15]. Thus,
adaptation to these two structurally similar carbon
sources appears to be highly specific among different
infant gut-associated bifidobacteria. If this is true,
then the role of mucolytic taxa in the infant gut is
unclear. Further, to what extent is mucus degraded
in the infant gut and which taxa are responsible? To
begin to address these questions, a library of known
colonic mucin-derived O-glycans was compiled and
used to query untargeted mass spectra of fecal samples from infants from a previous study [16,17]. We
hypothesized that the previously demonstrated modification of the gut microbiome resulted in the modulation of mucin degradation by gut microbes. A
second part of the hypothesis was that colonization
with B. infantis, which does not degrade mucin, and
the subsequent reduction in mucolytic taxa would
diminish mucin degradation, as measured by the
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abundance of freed colonic mucin-derived O-glycans
in the infant’s stool.

Materials and methods
Fecal sample collection and analysis
To examine the effect of Bifidobacterium longum subsp.
infantis (B. infantis) EVC001 colonization on gut mucin
degradation at day 29 postnatal, fecal samples were collected from healthy, breastfed infants fed 1.8 9 1010 CFU
per day B. longum subsp. infantis EVC001 from Day 7
postnatal to Day 29 postnatal (n = 9) and healthy breastfed
infants who were not fed B. longum subsp. infantis EVC001
(n = 10). These samples were randomly selected from the
larger study population for additional analysis using untargeted mass spectrometry data that had been collected initially for the study of human milk glycans found in the
infant’s feces. The initial clinical study was a partially randomized study, and subject populations, as well as ethical
approval for sample collection, were previously noted [16].
Demographics describing the randomly selected subset of
the total population examined in this analysis is presented
in Table S1.
The microbiome composition of these samples was also
previously determined. These data are publicly deposited in
the NCBI SRA (PRJNA390646) and were analyzed using
QIIME 1.9.1 [18] as previously described [17]. Briefly,
paired-end sequencing of the V4 region of the 16S rRNA
gene was performed on an Illumina MiSeq at the University
of California Davis Genome Center (Davis, CA). Openreference operational taxonomic unit (OTU) picking was
completed using UCLUST at 97% identity, and low-abundance OTUs were removed as recommended [19]. Across the
full data set, there was a mean of 9216 reads (SD  4505
reads) per sample and samples with at least than 2779 reads
were included for analysis. Here, 19 samples (n = 9, 10)
matching paired mass spectrometry data were selected from
this overall population and analyzed in the context of the
untargeted spectra as described below.

Analysis of spectra obtained with Nano-highperformance liquid chromatography-chip/time-offlight mass spectrometry (nano-LC-MS)
Oligosaccharide (OS) isolation and purification from these
fecal samples were performed previously and reported by
Frese et al. [17]. The structures of human colonic mucin
O-glycans were characterized by analysis on a nanoHPLC-Chip-TOF mass spectrometer using the methods
described by Davis et al. [20], and this approach was
previously reported for these samples where the concentration of structurally similar HMOs was determined [17].
Briefly, the high-performance liquid chromatography
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(HPLC) system used was an Agilent 1200 series unit with
a microfluidic chip, which was coupled to an Agilent
6220 series time of flight (TOF) mass spectrometer via
chip cube interface. The capillary pump on the chromatography unit loaded the sample onto the 40-nL
enrichment column at a flow rate of 4.0 lLmin 1 with a
1 lL injection volume. A nano pump was used for analyte separation on the analytical column, which was
75 9 43 mm and packed with porous graphitized carbon.
Separation was accomplished using a binary gradient of
aqueous solvent A [3% acetonitrile (ACN)/water (v/v) in
0.1% formic acid (FA)] and organic solvent B [90%
ACN/water (v/v) in 0.1% FA] using a method developed
for HMO separation (7, 8). The sample was introduced
into the TOF mass spectrometer via electrospray ionization, which was tuned and calibrated using a dual nebulizer electrospray source with calibrant ions ranging from
m/z 118.086 to 2721.895, and data were collected in the
positive mode. These untargeted spectra were analyzed in
the present study as described below.

Glycan data analysis
The untargeted mass spectra were collected (as above) and
analyzed using Agilent MassHunter Workstation Data
Acquisition version B.02.01 on the nano-HPLC-Chip-TOF.
The ‘Find Compounds by Molecular Feature’ function of
the software was used to identify mucin glycan species
within 20 ppm of theoretical masses. Compound abundances were expressed as volume in ion counts that corresponded to absolute abundances of the compounds in each
sample. 1HexNAc-1NeuAc, 1HexNAc-1Hex-NeuAc, 2HexNAc-1NeuAc, 2HexNAc-1Hex-1Fuc, 2HexNAc-1Hex1NeuAc, 2HexNAc-1Hex-2Fuc, 3HexNAc-1Hex-1Fuc, 2He

A

Control

xNAc-1Hex-1Fuc-1NeuAc,
2HexNAc-1Hex-1Fuc-2Neu
Ac, 3HexNAc-1Hex-2NeuAc and 3HexNAc-1Hex-2Fuc1NeuAc were monitored as they are discriminatively
human colonic mucin O-glycans [21].

Statistical analysis
Multiple t-tests, corrected using the Holm–Sidak method for
multiple comparisons, were carried out in Graph Pad Prism
7 (GRAPHPAD Software, La Jolla, CA, USA). Wilcoxon ranksum test was used for single comparisons. P values, or
adjusted P values, of 0.05 or less in comparisons were considered significantly different. Differences in bacterial community composition and colonic mucin-derived O-glycans were
calculated in several, complementary ways. First, a weighted
UniFrac distance matrix [22] was used to visualize differences in community composition according to treatment
group using principal coordinate analysis (PCoA). Second, a
Bray–Curtis dissimilarity index between all colonic mucinderived O-glycan species was visualized via PCoA. To evaluate the effect size of EVC001 colonization, both weighted
UniFrac and Bray–Curtis dissimilarity matrices were tested
via Permanova multivariate comparisons with 999 permutations and FDR-corrected P-values. Mantel tests were used to
assess significant relationships between the phylogenetic distance of the bacterial communities and the colonic mucinderived O-glycan abundance. Colonic mucin-derived O-glycan abundance was transformed to dissimilarity matrices
using Euclidean distance, while phylogenetic distance was
obtained via the weighted UniFrac algorithm. Tests were
performed using Pearson’s product-moment correlation coefficient (r) with 999 permutations and a two-tailed test.
To compute specific correlations between observations of
bacterial taxa and colonic mucin-derived O-glycan
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Fig. 1. (A) The relative abundance of the taxa, as reported at the family level by Frese et al. 2017, of each fecal sample in this analysis. (B)
PCoA of the gut microbiome at the family level; control (CON) samples are shown as gray points, and EVC001-fed infant samples are
shown as teal points. 87.5% of total variation was described in the first two principal components (PC1 and PC2). PERMANOVA
comparisons identified a significant difference between the two treatment groups by composition (R = 26.5, P = 0.001).

FEBS Open Bio 8 (2018) 1649–1657 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

1651

B. longum subsp. infantis EVC001 and colonic mucins

structures, a Spearman’s q test was used. Raw correlation
statistics were tested for likelihood using Fisher’s Z transformation and P-values corrected via Benjamini–Hochberg
false discovery rate (FDR) procedure.

Results and Discussion
Comparisons of the gut microbiome among a
subselected cohort
The gut microbiome of samples analyzed by mass
spectrometry from infants profiled by Frese et al. is
shown in Fig. 1A. Infants were fed 1.8 x 1010 CFU
per day of B. infantis EVC001 for 21 days from Day
7 to Day 29 postnatal. Infants fed EVC001 had

S. Karav et al.

significantly high levels of Bifidobacterium and significantly lower levels of Bacteroides than control
infants not fed B. infantis EVC001. Bacteroides was
the predominant mucolytic taxon identified in the
samples [23]. Notably, B. infantis fails to grow on
colonic mucin as a sole carbon source [15], and the
relative abundance of Bacteroidaceae was negatively
correlated with the abundance of Bifidobacteriaceae
(Spearman’s q = 0.65; P = 0.0029). Among the 19
samples profiled by nano-HPLC-Chip-TOF here, the
gut microbiome profiles for nine infants fed B. infantis EVC001 were significantly different as tested by
PERMANOVA (R = 26.5, P = 0.001) from that of
the 10 control infants (Fig. 1B). Even when all Bifidobacterium-matched reads were filtered from the
B
Number of colonic mucin-derived O-glycans

A

Total Number of OS species detected

***
500
400
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0
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O-glycans in glycan Pool
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EVC001-fed
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Fig. 2. Comparison of fecal glycome and colonic mucin-derived O-glycans of control and EVC001-fed infant feces. (A) Total number of OS
detected across treatment groups. (B) Number of colonic mucin-derived O-glycans across treatment groups. (C) Relative abundance of the
total number of colonic mucin-derived O-glycans in the total OS pool across treatment groups. (D) Percent of the OS assigned to colonic
mucin-derived O-glycans in the total OS abundance across treatment groups.
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samples, the residual microbial communities were
still significantly different according to treatment
group when compared by PERMANOVA (R = 13.8,
P = 0.001).
Fecal glycomics indicates differences among
release of colonic mucin-derived O-glycans from
glycoproteins in vivo
The total OS compositions of the samples were determined by the untargeted approach of nano-HPLCChip-TOF. The compounds were characterized using
previously published libraries [21,24–26]. Among these
compositions, free HMOs and free colonic mucinderived O-glycans were found in the infant fecal glycome. The main focus of this study was to understand
the degradation of human colonic mucin glycans by
different gut microbiome profiles. This was determined
as the difference between a gut microbiome from
infants colonized with B. infantis EVC001 and microbiomes with a greater abundance of mucolytic taxa,
such as Bacteroidaceae. As target molecules, 1HexNAc1NeuAc,
1HexNAc-1Hex-NeuAc,
2H
exNAc-1NeuAc, 2HexNAc-1Hex-1Fuc, 2HexNAc1Hex-1NeuAc, 2HexNAc-1Hex-2Fuc, 3HexNAc-1Hex-

Associations between colonic mucin degradation
and the fecal microbiome

CON
EVC001-fed

PC2 (17.1%)

0.2

0.0

−0.2

−0.4

R = 12.4
P = 0.001
−0.25

1Fuc, 2HexNAc-1Hex-1Fuc-1NeuAc, 2HexNAc-1Hex1Fuc-2NeuAc, 3HexNAc-1Hex-2NeuAc and 3HexNAc-1Hex-2Fuc-1NeuAc were selected as typical
human colonic mucin glycans, as shown by Robbe
et al. [21]. The mass spectrometry monitoring these
structures showed that the number of total OS structures (including isomers and anomers) in samples from
control and EVC001-fed infants ranged from
67.4  19.81
and
360.44  102.52,
respectively
(P < 0.001; Fig. 2A). Although the control samples
contained fewer total OS structures, the number of
freed human colonic mucin-derived O-glycans of the
total OS was significantly higher 25.4 (8.09), whereas
only 6.33 (2.24) structures were colonic mucin-derived
O-glycans in samples from EVC001-fed infants
(P < 0.001, Wilcoxon test; Fig. 2B). As a proportion,
the relative abundance of colonic mucin-derived O-glycans was significantly higher in control samples than in
samples from EVC001-fed infants in terms of both the
number
of
structures
(37.68%  3.14%
and
1.78%  0.385%, respectively; Fig. 2C, P < 0.001,
Wilcoxon test) and their proportion of the total OS
profile (26.98%  8.48% and 1.68  1.12%, respectively;
Fig. 2D, P < 0.001, Wilcoxon test).

0.00

0.25

0.50

PC1 (46.2%)
Fig. 3. PCoA of colonic mucin-derived O-glycan composition
among samples using a Bray–Curtis dissimilarity index; control
(Con) samples are shown as gray points, and EVC001-fed infant
samples are shown as teal points. 63.3% of total variation was
explained in the first two principal components (PC1 and PC2).
PERMANOVA comparisons identified a significant difference
between the two groups, with respect to colonic mucin-derived Oglycan composition (R = 12.4; P = 0.001).

Overall, freed colonic mucin O-glycan composition differed significantly between EVC001-colonized and control infants when tested via PERMANOVA (R = 12.4,
P = 0.001; Fig. 3). However, to compare the composition of the gut microbiome with the abundance of
both total colonic mucin-derived O-glycans and the
specific structures monitored here, a Mantel test was
used to correlate these structures with the overall
microbiome composition. Broadly, the total colonic
mucin-derived O-glycan abundance was significantly
correlated with the microbiome composition (Mantel’s
R = 0.39, P = 0.01). Of these, only 1_0_0_1 (Mantel’s
R = 0.22, P = 0.05), 1_1_0_1 (Mantel’s R = 0.3, P =
0.027), 2_1_1_0 (Mantel’s R = 0.46, P = 0.003),
2_1_1_1 (Mantel’s R = 0.42, P = 0.003), 2_1_2_0
(Mantel’s R = 0.69, P = 0.001), 3_1_1_0 (Mantel’s
R = 0.35, P = 0.011), and 3_1_2_1 (Mantel’s R = 0.37,
P = 0.005) were significantly associated with specific
microbiome compositions.
To examine the interactions of the gut microbiome
and the colonic mucin-derived O-glycan species, a
Pearson correlation was calculated for all taxa and
structures in the samples, as well as the total abundance and proportion of colonic mucin-derived O-glycan species (Table 1). Bifidobacteriaceae abundance
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Table 1. Colonic mucin-derived O-glycan structure, composition, mass, and volume in samples from the two treatment groups.

Glycan
code
1_0_0_1
1_1_0_1
2_0_0_1
2_1_1_0
2_1_0_1
2_1_2_0
3_1_1_0
2_1_1_1
2_1_1_2
3_1_0_2
3_1_2_1

Composition

Neutral
mass

Log10 volume
control
[Mean (SD)]

Log10 volume
EVC001-fed [Mean (SD)]

Holm–Sidak adjusted
P value

1HexNAc-1NeuAc
1HexNAc-1Hex-1NeuAc
2HexNAc-1NeuAc
2HexNAc-1Hex-1Fuc
2HexNAc-1Hex-1NeuAc
2HexNAc-1Hex-2Fuc
3HexNAc-1Hex-1Fuc
2HexNAc-1Hex-1Fuc-1NeuAc
2HexNAc-1Hex-1Fuc-2NeuAc
3HexNAc-1Hex-2NeuAc
3HexNAc-1Hex-2Fuc-1NeuAc

512
675
716
735
878
879
936
1024
1315
1372
1373

7.19
5.96
5.93
6.17
5.9
6.45
6.43
7.31
7.08
6.43
7.52

5.44
4.06
0
0
5.5
5.46
5.32
5.42
6.71
5.25
5.77

0.010659
0.09968
0.258702
0.09968
0.502866
3.13E-06
0.015609
0.000189
0.502866
0.141386
0.000895

(7.08)
(6.01)
(6.16)
(6.23)
(6.11)
(5.95)
(6.31)
(7.01)
(7.26)
(6.52)
(7.28)

(5.55)
(4.53)
(0)
(0)
(5.56)
(5.51)
(5.43)
(5.54)
(7.02)
(5.4)
(5.85)

Table 2. Correlational analysis comparing microbiome composition (Mantel test) and specific bacterial families (Spearman’s q) with colonic
mucin-derived O-glycans.
Spearman’s q

Mucin-glycan Structures

Mantel r

Mantel P-value

Bacterial family

Total

0.39

0.01

1_0_0_1

0.22

0.05

Bifidobacteriaceae
Enterobacteriaceae
Pasteurellaceae
Bifidobacteriaceae
Enterobacteriaceae
Bacteroidaceae

0.66
0.63
0.61
0.65
0.63
0.63

0.04
0.04
0.04
0.03
0.03
0.03

1_1_0_1
2_0_0_1
2_1_0_1
2_1_1_0

0.3
0.03
0.07
0.46

0.027
0.826
0.590
0.003

2_1_1_1

0.42

0.003

Clostridiaceae
Planococcaceae
Bifidobacteriaceae
Bacteroidaceae
Bifidobacteriaceae

0.7
0.63
0.63
0.69
0.67

0.01
0.03
0.03
0.01
0.01

2_1_1_2
2_1_2_0

0.19
0.69

0.109
0.001

Bifidobacteriaceae
Bacteroidaceae
Enterobacteriaceae

0.82
0.72
0.71

7.85E-05
0.003
0.003

3_1_0_2
3_1_1_0
3_1_2_1

0.25
0.35
0.37

0.062
0.011
0.005

was significantly and negatively correlated with the
abundance of colonic mucin-derived O-glycans, as a
whole (Spearman’s q = 0.66, P = 0.04), whereas
Bacteroidaceae was significantly and positively correlated with the abundance of 1_0_0_1, 2_1_1_1,
3_1_2_1, and 2_1_2_0 (Table 2). Interestingly, Enterobacteriaceae, who are unlikely to degrade mucus
themselves, were significantly correlated with the overall abundance of colonic mucin-derived O-glycans
(Spearman’s q = 0.061, P = 0.04) as well as 1_0_0_1
(Spearman’s q = 0.63, P = 0.03), and 2_1_2_0 (Spearman’s q = 0.71, P = 0.003). Similarly, Clostridiaceae
1654

P-value (FDR)

(Spearman’s q = 0.7, P = 0.01) and Planococcaceae
(Spearman’s q = 0.63, P = 0.03) were significantly
correlated with 2_1_1_0. While Pasteurellaceae were
significantly correlated with the overall abundance of
colonic mucin-derived O-glycans, they were not associated with specific O-glycan species. Interestingly,
three of these colonic mucin-derived O-glycan species
(1_1_1_0, 3_1_1_0 and 3_1_2_1) were significantly
associated with microbiome compositions, but no
individual taxa were responsible for this association.
The broad associations between diminished abundance, number, and proportion of colonic mucin-
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derived O-glycans and colonization by B. infantis
EVC001 was reflected in the negative correlations
between the abundance of Bifidobacteriaceae and both
total colonic mucin-derived O-glycan abundance and
four of the mucin-derived O-glycan species monitored
here. Similarly, the abundance of a known mucindegrading family, Bacteroidaceae, was positively correlated with the abundance of these same structures.
Many Bacteroides species allocate a large proportion
of their genome to harvesting polysaccharides, including mucin [27], and the significant positive correlation
with colonic mucin-derived O-glycan concentrations
supports these previous findings, even though 16S
rRNA gene sequencing here does not confidently distinguish between OTUs at the species level. Many of
the genes associated with polysaccharide utilization
common to mucin-degrading Bacteroides are highly
active on mucin glycoproteins, including the O-glycan
cores found in human colonic mucin, as evidenced
here. Bacteroides can grow on mucin a sole carbon
source and have specific transcriptional responses to
incubation with mucin [13]. In particular, Bacteroides
broadly possess enzymes from glycosyl hydrolase (GH)
family GH 84, GH 85, GH 89, GH 101, and GH 129
that are active on mucin glycoproteins and may facilitate the release of these glycans from the mucin protein [13,27,28]. The release of these structures may
facilitate the growth of taxa which are potentially
pathogenic (e.g., Clostridiaceae and Enterobacteriaceae), and sialylated and fucosylated glycans derived
from host mucin have been shown to play a major role
in disease pathogenesis by Salmonella, Clostridium difficile, and cytotoxic Escherichia coli [9] and taxa that
act as reservoirs of virulence factors in the infant gut
[29].

Conclusion
The human gastrointestinal epithelium is protected by
a layer of mucus. Mucin, as a glycoprotein, is coated
with a wide variety of conjugated glycans that can
serve as a carbon source for mucolytic bacteria, and
their release may facilitate the growth of other taxa
such as Enterobacteriaceae and Clostridiaceae. Specifically, human colon mucins contain unique O-glycan
structures that can be utilized only by few mucolytic
taxa, and in breastfed infants, the predominant mucolytic taxon was Bacteroidaceae. These bacteria harbor
multiple GH-encoding genes that facilitate the liberation of colonic mucin O-glycan from glycoproteins.
Our results show that gut microbiomes of infants colonized by B. infantis have diminished mucin degradation, as evidenced by reduced abundance and diversity
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of freed colonic mucin-derived O-glycans, as well as
the negative correlations between these and Bifidobacteriaceae. B. infantis is not able to cleave colonic
mucin-derived O-glycans, and their colonization is
associated with diminished populations of Bacteroidaceae [17]. Infants with a gut microbiome with
higher relative abundance of mucolytic taxa have
enhanced mucin degradation, and this may have longterm health consequences, or increase their susceptibility to infection from taxa harboring virulence factors
via cross-feeding [6,9,29]. Further studies are required
to determine the specific negative effects of mucin
degradation, the role of these taxa in diminishing host
gut barrier function, and any functional consequences
to the host.

Acknowledgements
Spectra were collected in the laboratory of Carlito
Lebrilla, to whom the authors are extremely grateful.
The authors also thank Cora Morgan for critical editing of the manuscript.

Author contributions
SK performed the analysis of the mass spectra. SF
and GC performed statistical tests and microbiome
analyses. All authors contributed to the study, read,
and approved the final manuscript.

Conflict of interest
SAF and GC are employed by Evolve Biosystems,
Inc., which funded the study from which these samples
were derived.

References
1 Brockhausen I and Stanley P (2017) O-GalNAc
Glycans. In Essentials of Glycobiology [Internet] (Varki
A, Cummings RD, Esko JD, Freeze HH, Stanley P,
Bertozzi CR, Hart GW and Etzler ME, eds), Chapter
10, 3rd edn. Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY.
2 Robbe C, Capon C, Coddeville B and Michalski JC
(2004) Structural diversity and specific distribution of
O-glycans in normal human mucins along the intestinal
tract. Biochem J 384, 307–316.
3 Holmen Larsson JM, Karlsson H, Sj€
ovall H and
Hansson GC (2009) A complex, but uniform Oglycosylation of the human MUC2 mucin from colonic
biopsies analyzed by nanoLC/MS n. Glycobiology 19,
756–766.

FEBS Open Bio 8 (2018) 1649–1657 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

1655

B. longum subsp. infantis EVC001 and colonic mucins

4 Lombard V, Golaconda Ramulu H, Drula E, Coutinho
PM and Henrissat B (2013) The carbohydrate-active
enzymes database (CAZy) in 2013. Nucleic Acids Res
42, D490–D495.
5 Tailford LE, Crost EH, Kavanaugh D and Juge N
(2015) Mucin glycan foraging in the human gut
microbiome. Front Genet 6, 81.
6 Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB,
Kashyap PC, Gopinath S, Naidu N, Choudhury B,
Weimer BC, Monack DM et al. (2013) Microbiotaliberated host sugars facilitate post-antibiotic expansion
of enteric pathogens. Nature 502, 96.
7 Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K
and Podolsky DK (1995) Trefoil peptide protection of
intestinal epithelial barrier function: cooperative
interaction with mucin glycoprotein. Gastroenterology
109, 516–523.
8 Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford
E, Thomsson KA, McGee S, Mansour L, Tong M
et al. (2011) Loss of intestinal core 1–derived O-glycans
causes spontaneous colitis in mice. J Clin Investig 121,
1657–1666.
9 Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R,
Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner
EM, Huso DL et al. (2018) Patients with familial
adenomatous polyposis harbor colonic biofilms
containing tumorigenic bacteria. Science 359, 592–597.
10 Liu B and Newburg DS (2013) Human milk
glycoproteins protect infants against human pathogens.
Breastfeed Med 8, 354–362.
11 German JB, Freeman SL, Lebrilla CB and Mills DA
(2008) Human milk oligosaccharides: evolution,
structures and bioselectivity as substrates for intestinal
bacteria. In Personalized Nutrition for the Diverse Needs
of Infants and Children (Bier DM, German JB and
L€
onnerdal B, eds), pp. 205–222. Karger Publishers,
Basel, Switzerland.
12 Marcobal A and Sonnenburg J (2012) Human milk
oligosaccharide consumption by intestinal microbiota.
Clin Microbiol Infect 18, 12–15.
13 Marcobal A, Barboza M, Sonnenburg ED, Pudlo N,
Martens EC, Desai P, Lebrilla CB, Weimer BC, Mills
DA, German JB et al. (2011) Bacteroides in the infant
gut consume milk oligosaccharides via mucus-utilization
pathways. Cell Host Microbe 10, 507–514.
14 Turroni F, van Sinderen D and Ventura M (2011)
Genomics and ecological overview of the genus
Bifidobacterium. Int J Food Microbiol 149, 37–44.
15 Garrido D, Ruiz-Moyano S, Lemay DG, Sela DA,
German JB and Mills DA (2015) Comparative
transcriptomics reveals key differences in the response
to milk oligosaccharides of infant gut-associated
bifidobacteria. Sci Rep 5, 13517.
16 Smilowitz JT, Moya J, Breck MA, Cook C, Fineberg
A, Angkustsiri K and Underwood MA (2017) Safety

1656

S. Karav et al.

17

18

19

20

21

22

23

24

25

26

27

and tolerability of Bifidobacterium longum subspecies
infantis EVC001 supplementation in healthy term
breastfed infants: a phase I clinical trial. BMC Pediatr
17, 1–11.
Frese SA, Hutton AA, Contreras LN, Shaw CA,
Palumbo MC, Casaburi G, Xu G, Davis JCC, Lebrilla
CB, Henrick BM et al. 2017 Persistence of supplemented
bifidobacterium longum subsp infantis EVC001 in
Breastfed Infants. mSphere 2, e00501–e00517
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K,
Bushman FD, Costello EK, Fierer N, Pe~
na AG,
Goodrich JK, Gordon JI et al. (2010) QIIME allows
analysis of high-throughput community sequencing
data. Nat Methods 7, 335–336.
Bokulich NA, Subramanian S, Faith JJ, Gevers D,
Gordon JI, Knight R, Mills DA and Caporaso JG
(2013) Quality-filtering vastly improves diversity
estimates from Illumina amplicon sequencing. Nat
Methods 10, 57.
Davis JC, Totten SM, Huang JO, Nagshbandi S,
Kirmiz N, Garrido DA, Lewis ZT, Wu LD, Smilowitz
JT, German JB et al. (2016) Identification of
oligosaccharides in feces of breast-fed infants and their
correlation with the gut microbial community. Mol Cell
Proteomics 15, 2987–3002.
Robbe C, Capon C, Coddeville B and Michalski JC
(2004) Diagnostic ions for the rapid analysis by nanoelectrospray ionization quadrupole time-of-flight mass
spectrometry of O-glycans from human mucins. Rapid
Commun Mass Spectrom 18, 412–420.
Lozupone C and Knight R (2005) UniFrac: a new
phylogenetic method for comparing microbial
communities. Appl Environ Microbiol 71, 8228–8235.
Shaffer M and Lozupone C (2018) Prevalence and
source of fecal and oral bacteria on infant, child, and
adult hands. mSystems 3, e00192–17.
Matamoros S, Gras-Leguen C, Le Vacon F, Potel G
and de La Cochetiere MF (2013) Development of
intestinal microbiota in infants and its impact on
health. Trends Microbiol 21, 167–173.
Karav S and Le Parc A, Leite Nobrega de Moura Bell
JM, Frese SA, Kirmiz N, Block DE, Barile D and
Mills DA (2016) Oligosaccharides released from milk
glycoproteins are selective growth substrates for infantassociated bifidobacteria. Appl Environ Microbiol 82,
3622–3630.
Thomsson KA, Prakobphol A, Leffler H, Reddy MS,
Levine MJ, Fisher SJ and Hansson GC (2002) The
salivary mucin MG1 (MUC5B) carries a repertoire of
unique oligosaccharides that is large and diverse.
Glycobiology 12, 1–14.
Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK,
Chiang HC, Hooper LV and Gordon JI (2003) A
genomic view of the human-Bacteroides
thetaiotaomicron symbiosis. Science 299, 2074–2076.

FEBS Open Bio 8 (2018) 1649–1657 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

S. Karav et al.

28 Comstock LE (2009) Importance of glycans to the hostbacteroides mutualism in the mammalian intestine. Cell
Host Microbe 5, 522–526.
29 Casaburi G and Frese SA (2018) Colonization of
breastfed infants by Bifidobacterium longum subsp.
infantis EVC001 reduces virulence gene abundance.
Hum Microbiome J 9, 7–10.

B. longum subsp. infantis EVC001 and colonic mucins

Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Table S1. Study participant demographics showing the
mean (standard deviation) or number per group.

FEBS Open Bio 8 (2018) 1649–1657 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

1657

